Kaiyang Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaiyang Tang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ce Luo
Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
1 shared publication - Deng Pan
Tsinghua-Peking Center for Life Sciences, Department of Basic Medical Sciences, Tsinghua University, Beijing, China
1 shared publication - Di Feng
Global Computational Biology and Data Science Department, Boehringer Ingelheim, Ridgefield, Connecticut
1 shared publication - Jie Dai
Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharmaceuticals, Inc. 4 , Ridgefield, CT
1 shared publication - Lijian Wu
School of Basic Medical Sciences, State Key Laboratory of Molecular Oncology, Tsinghua University 1 , Beijing
1 shared publication - Linjie Tong
School of Basic Medical Sciences, State Key Laboratory of Molecular Oncology, Tsinghua University 1 , Beijing
1 shared publication
Latest Publications
- 20 August 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Perturbation of calreticulin potentiates CD8+ T cell–mediated antitumor immunity
Effective immunotherapy relies on the presentation of tumor-derived neoantigens on the major histocompatibility complex class I (MHC-I) to activate CD8+ T cells. Deficiencies in this process are a key mechanism of immune evasion and resistance to checkpoint blockade. In this study, using an in vivo CRISPR-Cas9 screen, we unexpectedly found that inactivation of calreticulin (CALR), and other selected components of the peptide-loading complex (PLC), induced robust CD8+ T cell–mediated immune responses. We show that this effect is dependent on the expression of classical MHC-I on tumor cells. Mechanistically, loss of CALR reshaped the MHC-I peptide repertoire, favoring the presentation of low-affinity peptides in murine and human cell lines. Genetic or pharmacological inhibition of PDIA3, another PLC component, similarly induced antitumor effects. These findings reveal a previously unrecognized role of CALR and the PLC in regulating antitumor immunity and suggest that targeting this pathway could be a promising strategy to overcome immune resistance and improve the efficacy of cancer immunotherapies.
- 20 August 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (10)
Perturbation of calreticulin potentiates CD8+ T cell–mediated antitumor immunity
Effective immunotherapy relies on the presentation of tumor-derived neoantigens on the major histocompatibility complex class I (MHC-I) to activate CD8+ T cells. Deficiencies in this process are a key mechanism of immune evasion and resistance to checkpoint blockade. In this study, using an in vivo CRISPR-Cas9 screen, we unexpectedly found that inactivation of calreticulin (CALR), and other selected components of the peptide-loading complex (PLC), induced robust CD8+ T cell–mediated immune responses. We show that this effect is dependent on the expression of classical MHC-I on tumor cells. Mechanistically, loss of CALR reshaped the MHC-I peptide repertoire, favoring the presentation of low-affinity peptides in murine and human cell lines. Genetic or pharmacological inhibition of PDIA3, another PLC component, similarly induced antitumor effects. These findings reveal a previously unrecognized role of CALR and the PLC in regulating antitumor immunity and suggest that targeting this pathway could be a promising strategy to overcome immune resistance and improve the efficacy of cancer immunotherapies.